Understanding the Implementation of Cued Exercise Using Wearable Devices and a Custom Smartphone Application Following Bone Marrow Transplant.

Pilot Study to Understand the Feasibility of Implementing a Wearable Device Cueing System Following Bone Marrow Transplant

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06645132

Enrollment

Registered

2024-10-16

Start date

2024-10-28

Completion date

2025-09-30

Last updated

2025-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Cancer, Bone Marrow Transplant (BMT)

Brief summary

The purpose of this study is to pilot test the feasibility of providing patients diagnosed with a hematologic malignancy, undergoing an allogeneic bone marrow transplant, a wearable device and smartphone app (similar to a Fitbit), that would send personalized reminders to move during their post-transplant inpatient hospital stay to promote physical recovery and well-being.

Detailed description

Enrolled patients who have been diagnosed with a hematologic malignancy and are scheduled to undergo an allogeneic bone marrow transplant will use a custom-designed wearable device and smartphone application as a behavioral intervention to cue exercise. Participants will be asked to wear the wearable device for the duration of their post-transplant inpatient hospital stay. Aim 1. To examine the potential efficacy of the wearable device + smartphone application to prompt alloBMT patients to move. Aim 2. To receive participant feedback on their experience participating in the study.

Interventions

BEHAVIORALexercise intervention

Exercise intervention leveraging wearable devices and a custom smartphone application to cue exercise as a reminder during idle time during an inpatient hospital stay, post allogenic bone marrow transplant.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* At least 18 years of age * Diagnosed with hematologic malignancy * Scheduled to receive an alloBMT * Physician consent to participate in the study

Exclusion criteria

• Inability to complete 15 minutes walking unassisted

Design outcomes

Primary

Measure	Time frame	Description
Pilot evaluation of intervention efficacy	cumulative percent from day 1 through discharge from hospital, on average day 30	Efficacy will be evaluated by examining the percentage of time participants responded to the cued exercise prompts.
Patient feedback from participation in the study	day 10	Patient experience will be evaluated by looking at the central tendencies of the ratings from the post-participation evaluation survey.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026